Genetic variants in the NF-κB signaling pathway (NFKB1, NFKBIA, NFKBIZ) and risk of critical outcome among COVID-19 patients
Authors:
- 21 June 2022
- journal article
- research article
- Published by Elsevier in Human Immunology
- Vol. 83 (8-9) , 613-617
Abstract
No abstract availableKeywords
Funding Information
- Instituto de Salud Carlos III
This publication has 37 references indexed in Scilit:
- Common Polymorphisms in the NFKBIA Gene and Cancer Susceptibility: A Meta-AnalysisMedical Science Monitor, 2015
- NFκB1 and NFκBIA Polymorphisms Are Associated with Increased Risk for Sporadic Colorectal Cancer in a Southern Chinese PopulationPLOS ONE, 2011
- NF-κB, Inflammation, and Metabolic DiseaseCell Metabolism, 2011
- IκBζ is essential for natural killer cell activation in response to IL-12 and IL-18Proceedings of the National Academy of Sciences, 2010
- Inhibitor IκBα Promoter Functional Polymorphisms in Patients with Rheumatoid ArthritisJournal of Clinical Immunology, 2010
- IκBζ regulates TH17 development by cooperating with ROR nuclear receptorsNature, 2010
- NFKBIZ polymorphisms and susceptibility to pneumococcal disease in European and African populationsGenes & Immunity, 2009
- Activation of endothelial intrinsic NF-κB pathway impairs protein C anticoagulation mechanism and promotes coagulation in endotoxemic miceBlood, 2009
- A Pivotal Role of Endothelial-Specific NF-κB Signaling in the Pathogenesis of Septic Shock and Septic Vascular DysfunctionThe Journal of Immunology, 2009
- Signaling to NF-κBGenes & Development, 2004